Cwm, LLC Biocryst Pharmaceuticals Inc Transaction History

Cwm, LLC

$33.3 Billion
Q3 2025

A detailed history of Cwm, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Cwm, LLC holds 29,886 shares of BCRX stock, worth $207,109. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,886

Previous 47,335 36.86%

Holding current value

$207,109

Previous $424,000 46.46%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 15, 2025	SELL	$7.55 - $9.06 $131,739 - $158,087	-17,449 Reduced 36.86%	29,886 $227,000
Q2 2025 Jul 25, 2025	SELL	$6.41 - $11.19 $41,120 - $71,783	-6,415 Reduced 11.93%	47,335 $424,000
Q1 2025 May 01, 2025	BUY	$7.06 - $9.39 $237,611 - $316,029	33,656 Added 167.49%	53,750 $403,000
Q4 2024 Feb 04, 2025	BUY	$7.03 - $8.43 $21,244 - $25,475	3,022 Added 17.7%	20,094 $151,000
Q3 2024 Oct 08, 2024	BUY	$6.41 - $8.69 $73,163 - $99,187	11,414 Added 201.73%	17,072 $130,000
Q2 2024 Jul 09, 2024	BUY	$4.13 - $6.79 $15,578 - $25,611	3,772 Added 200.0%	5,658 $35,000
Q1 2024 Apr 05, 2024	BUY	$4.89 - $7.65 $1,574 - $2,463	322 Added 20.59%	1,886 $10,000
Q4 2023 Feb 01, 2024	SELL	$4.98 - $6.77 $9,795 - $13,316	-1,967 Reduced 55.71%	1,564 $9,000
Q3 2023 Oct 11, 2023	BUY	$6.71 - $7.92 $120 - $142	18 Added 0.51%	3,531 $25,000
Q2 2023 Aug 03, 2023	SELL	$6.96 - $8.81 $292 - $370	-42 Reduced 1.18%	3,513 $25,000
Q1 2023 Apr 28, 2023	SELL	$7.94 - $11.84 $579 - $864	-73 Reduced 2.01%	3,555 $30,000
Q4 2022 Feb 01, 2023	BUY	$10.5 - $14.2 $2,257 - $3,053	215 Added 6.3%	3,628 $42,000
Q1 2021 Sep 15, 2021	SELL	$7.37 - $13.61 $1,842 - $3,402	-250 Reduced 6.83%	3,413 $54,000
Q1 2021 Apr 27, 2021	BUY	$7.37 - $13.61 $1,842 - $3,402	250 Added 7.32%	3,663 $37,000
Q4 2020 Sep 15, 2021	SELL	$3.37 - $8.61 $842 - $2,152	-250 Reduced 6.83%	3,413 $54,000
Q4 2020 Jan 27, 2021	BUY	$3.37 - $8.61 $842 - $2,152	250 Added 7.32%	3,663 $27,000
Q3 2020 Sep 15, 2021	BUY	$3.43 - $5.53 $7,419 - $11,961	2,163 Added 173.04%	3,413 $54,000
Q3 2020 Oct 19, 2020	SELL	$3.43 - $5.53 $7,419 - $11,961	-2,163 Reduced 63.38%	1,250 $4,000
Q2 2020 Sep 15, 2021	BUY	$1.9 - $5.61 $4,109 - $12,134	2,163 Added 173.04%	3,413 $54,000
Q2 2020 Jul 22, 2020	SELL	$1.9 - $5.61 $4,109 - $12,134	-2,163 Reduced 63.38%	1,250 $6,000
Q1 2020 Sep 15, 2021	BUY	$1.6 - $4.11 $5,460 - $14,027	3,413 New	3,413 $54,000
Q1 2020 Apr 28, 2020	SELL	$1.6 - $4.11 $5,460 - $14,027	-3,413 Closed	0 $0
Q4 2019 Sep 14, 2021	BUY	$1.59 - $3.45 $5,426 - $11,774	3,413 New	3,413 $54,000
Q4 2019 Jan 27, 2020	SELL	$1.59 - $3.45 $5,426 - $11,774	-3,413 Closed	0 $0
Q3 2019 Sep 14, 2021	BUY	$2.5 - $3.73 $8,532 - $12,730	3,413 New	3,413 $54,000
Q3 2019 Oct 22, 2019	SELL	$2.5 - $3.73 $8,532 - $12,730	-3,413 Closed	0 $0
Q2 2019 Sep 14, 2021	BUY	$2.91 - $9.15 $9,931 - $31,228	3,413 New	3,413 $54,000
Q2 2019 Jul 31, 2019	SELL	$2.91 - $9.15 $9,931 - $31,228	-3,413 Closed	0 $0
Q1 2019 Sep 02, 2021	BUY	$7.38 - $9.72 $25,187 - $33,174	3,413 New	3,413 $0

Others Institutions Holding BCRX

# of Institutions

314

Shares Held

201M

Call Options Held

930K

Put Options Held

553K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.29B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account